Overlapping risk factors for diabetic ketoacidosis in patients with type 1 diabetes on ipragliflozin: case analysis of spontaneous reports in Japan from a pharmacovigilance safety database-Reference-Cited by-同舟云学术

Overlapping risk factors for diabetic ketoacidosis in patients with type 1 diabetes on ipragliflozin: case analysis of spontaneous reports in Japan from a pharmacovigilance safety database

Published:2023-04-11 Issue:8 Volume:22 Page:697-706
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Abiru Norio¹²,Nakatsuji Yoshino³,Noguchi Masahiro³,Tsuboi Keigo⁴

Affiliation:

1. Department of Endocrinology and Metabolism, Nagasaki University Graduate School of Biomedical Science, Nagasaki, Japan

2. Midori Clinic, Nagasaki, Japan

3. Pharmacovigilance, Astellas Pharma Inc., Tokyo, Japan

4. Medical Affairs, Astellas Pharma Inc., Tokyo, Japan

Funder

Astellas Pharma Inc

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2023.2193393

Reference35 articles.

1. Recommendations on the Proper Use of SGLT2 Inhibitors

2. Class effect for SGLT-2 inhibitors: a tale of 9 drugs

3. Development of SGLT1 and SGLT2 inhibitors

4. Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Innovations and applications of ketone body monitoring in diabetes care;Diabetology International;2024-05-28

2. Glucagon secretion and its association with glycaemic control and ketogenesis during sodium‐glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open‐label, prospective study;Diabetes, Obesity and Metabolism;2024-01-22

3. Unexpected Acute Hyperglycemia Following Pre-Surgical Discontinuation of SGLT2 Inhibitors in a Type 1 Diabetic Patient;American Journal of Case Reports;2023-05-23

4. Summary of Professor Liu Xun’s Experience in the Treatment of Type 2 Diabetes with Integrated Traditional Chinese and Western Medicine;Traditional Chinese Medicine;2023